Evidence map›Paper›PMID 38829854›Full record

ArticlePloS one2024

Age-dependent regulation of ELP1 exon 20 splicing in Familial Dysautonomia by RNA Polymerase II kinetics and chromatin structure.

Federico Riccardi, Giulia Romano, Danilo Licastro, Franco Pagani

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Federico RiccardiHuman Molecular Genetics, International Centre for Genetic Engineering and Biotechnology, Padriciano, Trieste, Italy.
Giulia RomanoHuman Molecular Genetics, International Centre for Genetic Engineering and Biotechnology, Padriciano, Trieste, Italy.ORCID 0000-0003-0356-4947
Danilo LicastroLaboratorio di Genomica ed Epigenomica, AREA Science Park, Padriciano, Trieste, Italy.
Franco PaganiHuman Molecular Genetics, International Centre for Genetic Engineering and Biotechnology, Padriciano, Trieste, Italy.ORCID 0000-0002-2678-3459

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial Dysautonomia (FD) is a rare disease caused by ELP1 exon 20 skipping. Here we clarify the role of RNA Polymerase II (RNAPII) and chromatin on this splicing event. A slow RNAPII mutant and chromatin-modifying chemicals that reduce the rate of RNAPII elongation induce exon skipping whereas chemicals that create a more relaxed chromatin exon inclusion. In the brain of a mouse transgenic for the human FD-ELP1 we observed on this gene an age-dependent decrease in the RNAPII density profile that was most pronounced on the alternative exon, a robust increase in the repressive marks H3K27me3 and H3K9me3 and a decrease of H3K27Ac, together with a progressive reduction in ELP1 exon 20 inclusion level. In HEK 293T cells, selective drug-induced demethylation of H3K27 increased RNAPII elongation on ELP1 and SMN2, promoted the inclusion of the corresponding alternative exons, and, by RNA-sequencing analysis, induced changes in several alternative splicing events. These data suggest a co-transcriptional model of splicing regulation in which age-dependent changes in H3K27me3/Ac modify the rate of RNAPII elongation and affect processing of ELP1 alternative exon 20.

Indexed as

Alternative SplicingChromatinDysautonomia, FamilialExonsRNA Polymerase IIAnimalsHEK293 CellsHistonesHumansKineticsMiceMice, TransgenicNerve Tissue ProteinsRNA SplicingTranscriptional Elongation FactorsChromatinElp1 protein, humanHistonesNerve Tissue ProteinsRNA Polymerase IITranscriptional Elongation Factors

Identifiers

PMID38829854
PMCPMC11146744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.